Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simris Alg ABFRA:5LU 28 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates FRA:5LU with a GF Score™ of 28/100. The stock has 6 warning signs investors should review. Among 968 Biotechnology companies, Simris Alg AB ranks worse than 73.97% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Simris Alg AB's Debt-to-Equity or its related term are showing as below:
FRA:5LU'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.44 Med: 0.12 Max: 0.36
Current: 0.47
During the past 12 years, the highest Debt-to-Equity Ratio of Simris Alg AB was 0.36. The lowest was -5.44. And the median was 0.12.
FRA:5LU's Debt-to-Equity is ranked worse than 73.97% of 968
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:5LU: 0.47
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Simris Alg AB Debt-to-Equity Related Terms
Simris Alg AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Simris Alg AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5LU vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Simris Alg AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simris Alg AB Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Simris Alg AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Simris Alg AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simris Alg AB (FRA:5LU) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Simris Alg AB and its competitors. According to the industry distribution chart, Simris Alg AB ranks #716 out of 968 companies in the Biotechnology industry, placing it in the top 74%.
Is Simris Alg AB's Debt-to-Equity too high?
Simris Alg AB's current Debt-to-Equity is 0.00. Based on the distribution chart, Simris Alg AB ranks #716 out of 968 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Simris Alg AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Simris Alg AB's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Simris Alg AB ranks #716 out of 968 companies for Debt-to-Equity. This places Simris Alg AB in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Simris Alg AB and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simris Alg AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simris Alg AB stock overvalued right now?
Simris Alg AB (FRA:5LU) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Simris Alg AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Simris Alg AB (FRA:5LU), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.
28GF Score
Get the complete analysis for FRA:5LU
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5LU has been successfully added to your 
